1. Pink Sheet

Acetaminophen Overdose Risk Persists Despite Label Changes – Study

 
• By Elizabeth Crawford

Many consumers do not closely read OTC painkiller labels and often do not adhere to package or label instructions, researchers say. Many likely are unaware of or ignore label changes industry voluntarily made and FDA ordered to reduce the risk of liver toxicity due to unintentional overdose.

The addition of liver toxicity and overdose risk warnings to acetaminophen labels may not be enough to reduce the high prevalence of overdosing of the painkiller, say researchers in a recent study.

The authors state in the May 26 Journal of General Internal Medicine that interviews with 500 adults between September 2009...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Pink Sheet for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Compliance

More from Pink Sheet

Merck’s Keytruda Gains Medicare Negotiation Reprieve With Expanded Orphan Exemption

 
• By Cathy Kelly

Bristol Myers Squibb’s Opdivo and Merck's Welireg also could benefit from the delay in Medicare price negotiation process eligibility.

US FDA’s Biologics Center Departures Grew Before More Than 100 RIFs Exited

 
• By Derrick Gingery

The Center for Biologics Evaluation and Research saw departures far outnumber new hires in the second and third quarters of FY 2025, before more than 100 people left July 14 after the reduction-in-force was finalized.

US FDA Cancer Reviewers Heading For The Exits, Potentially Impacting Review Timelines

 
• By Sarah Karlin-Smith

US FDA's cancer drugs division is feeling the effect of drug reviewer departures, despite efforts to keep them at the agency.